Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,006,866 papers from all fields of science
Search
Sign In
Create Free Account
BIM 46174
Known as:
BIM-46174
, BIM46174
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Cysteine
Imidazoles
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Tetrahydroimidazo[1,2‐a]pyrazine Derivatives: Synthesis and Evaluation as Gαq‐Protein Ligands
Jim Küppers
,
Tobias Benkel
,
+5 authors
M. Gütschow
Chemistry
2020
Corpus ID: 218756786
Abstract The 5,6,7,8‐tetrahydroimidazo[1,2‐a]pyrazine derivative BIM‐46174 and its dimeric form BIM‐46187 (1) are heterocyclized…
Expand
2019
2019
BIM-46174 fragments as potential ligands of G proteins.
Jim Küppers
,
Tobias Benkel
,
S. Annala
,
G. Schnakenburg
,
E. Kostenis
,
M. Gütschow
MedChemComm
2019
Corpus ID: 202067518
The 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine derivative BIM-46174 has received attention as Gαq inhibitor. We conducted…
Expand
2016
2016
Characterization of Rimonabant effects on G protein activity
A. Porcu
2016
Corpus ID: 87353954
G protein-coupled receptor (GPCRs) is the largest class of cell-surface receptors, and represents today the target of 40% of the…
Expand
2006
2006
Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.
G. Prévost
,
M. Lonchampt
,
+18 authors
P. Kasprzyk
Cancer Research
2006
Corpus ID: 11140009
A large number of hormones and local agonists activating guanine-binding protein-coupled receptors (GPCR) play a major role in…
Expand
2006
2006
Anticancer drugs: Downstream GPCR inhibition
C. Harrison
Nature reviews. Drug discovery
2006
Corpus ID: 42325870
10.1038/nrd2181 Although G-protein-coupled receptors (GPCRs) and their downstream signalling pathways are involved in cancer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required